Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00761215 | Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections | PHASE2 | COMPLETED | 192 | — | — | Sep 17, 2008 | Feb 24, 2009 | Nov 25, 2019 | 12 | United States |
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
| Arm | Type | Description |
|---|---|---|
| TR-701 200 mg | EXPERIMENTAL | - |
| TR-701 300 mg | EXPERIMENTAL | - |
| TR-701 400 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TR-701 200 mg | DRUG | oral TR-701 200 mg for 5 to 7 days |
| TR-701 300 mg | DRUG | oral TR-701 300 mg for 5 to 7 days |
| TR-701 400 mg | DRUG | TR-701 400 mg for 5 to 7 days |
Inclusion Criteria: * Diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms * Suspected or confirmed infection due to a gram-positive organism Exclusion Criteria: * Complicated skin and skin structure infection due to gram-negative organisms * Complicated...